U.S. Markets close in 18 mins

Boulder biotech firm beats expectations despite year-over-year losses on income, revenue

Jensen Werley
Boulder biotech firm beats expectations despite year-over-year losses on income, revenue

Array BioPharma Inc. (Nasdaq: ARRY) saw its revenue decline year-over-year and posted a loss per share, but still beat analyst expectations. The company saw $35.1 million in U.S. net product sales for its drug combination Braftovi + Mektovi. The company is also seeing its combination of Braftovi + Mektovi with the drugs cetuximab or pantimumab recommended as a treatment option by the national Comprehensive Cancer Network for patients with a certain form of colorectal cancer.